Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer

BJU International

Volumn 94, Issue 4, 2004, Pages 524-527

  Vordos, Dimitri ^a   Paule, Bernard ^a   Vacherot, Francis ^a   Allory, Yves ^a   Salomon, Laurent ^a   Hoznek, Andras ^a   Yiou, René ^a   Chopin, Dominique ^a   Abbou, Claude Clément ^a   De La Taille, Alexandre ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

Bisphosphonate; Chemotherapy; Docetaxel; Prostate cancer; Zoledronic acid

Indexed keywords

ANALGESIC AGENT; ANTIEMETIC AGENT; ANTIINFLAMMATORY AGENT; CIMETIDINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; MITOXANTRONE; NARCOTIC ANALGESIC AGENT; PARACETAMOL; PREDNISOLONE; PROSTATE SPECIFIC ANTIGEN; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; BLOOD TRANSFUSION; BONE DISEASE; BONE SCINTISCANNING; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER SURVIVAL; CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FRACTURE; HOME CARE; HUMAN; HYPERSENSITIVITY REACTION; MALE; METASTASIS; PAIN; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; SIDE EFFECT; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; DIPHOSPHONATES; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; PILOT PROJECTS; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 20844456971     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-4096.2004.04919.x     Document Type: Article

References (17)

1. Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14: 1756-64
2. Kantoff PW, Halabi S, Conaway M et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999; 17: 2506-13
3. Savarese DM, Halabi S, Hars V et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol 2001; 19: 2509-16
4. Picus J, Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol 1999; 26: 14-8
5. Friedland D, Cohen J, Miller R Jr et al. A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol 1999; 26: 19-23
6. Green JR. Bisphosphonates in cancer therapy. Curr Opin Oncol 2002; 14: 609-15
7. Saad F, Gleason DM, Murray R et al. Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-68
8. Magnetto S, Boissier S, Delmas PD, Clezardin P. Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int J Cancer 1999; 83: 263-9
9. Jagdev SP, Coleman RE, Shipman CM, Rostami HA, Croucher PI. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 2001; 84: 1126-34
10. Witters LM, Crispino J, Fraterrigo T, Green J, Lipton A. Effect of the combination of docetaxel, zoledronic acid, and a COX-2 inhibitor on the growth of human breast cancer cell lines. Am J Clin Oncol 2003; 26: S92-S97
11. Glass TR, Tangen CM, Crawford ED, Thompson I. Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol 2003; 169: 164-9
12. Bubley GJ, Carducci M, Dahut W et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17: 3461-7
13. Sabbatini P, Larson SM, Kremer A et al. Prognostic significance of extent of disease in bone in patients with androgen - independent prostate cancer. J Clin Oncol 1999; 17: 948-57
14. Small EJ, Bok R, Reese DM, Sudilovsky D, Frohlich M. Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer. Semin Oncol 2001; 28: 71-6
15. Petrylak DP, Macarthur RB, O'Connor J et al. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 1999; 17: 958-67
16. Hudes G, Einhorn L, Ross E et al. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: a Hoosier oncology group and Fox Chase Network phase III trial. J Clin Oncol 1999; 17: 3160-6
17. Beer TM, Pierce WC, Lowe BA, Henner WD. Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol 2001; 12: 1273-9